• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Clearside Biomedical Inc.

    4/18/25 8:05:07 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLSD alert in real time by email
    DEFA14A 1 2025_defa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    Filed by the Registrant ý

     

    Filed by a Party other than the Registrant ¨

    Check the appropriate box:

    ¨ Preliminary Proxy Statement

     

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨ Definitive Proxy Statement

     

    ý Definitive Additional Materials

     

    ¨ Soliciting Material under § 240.14a-12

     

    Clearside Biomedical, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply)

    ý No fee required

     

    ¨ Fee paid previously with preliminary materials

     

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    img213474020_0.jpg

     

     

     

     

     

     

    P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Clearside Biomedical, Inc. Annual Meeting of Stockholders Friday, May 30, 2025 8:00 AM, Eastern Time 900 North Point Parkway, Suite 200, Alpharetta, GA 30005 styleINA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on May 30, 2025 for Stockholders of Record as of April 1, 2025 To order materials for this and/or future stockholder meetings, use one of the following methods. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/CLSD To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 20, 2025. Internet: www.investorelections.com/CLSD Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    img213474020_1.jpg

    Clearside Biomedical, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 3 AND 4 PROPOSAL 1. Election of Directors 1.01 Anthony S. Gibney 1.02 George Lasezkay 1.03 Christy L. Shaffer 2. Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement. 3. Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. 4. Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 shares to 400,000,000 shares. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting, including any adjournment or postponement thereof.


    Get the next $CLSD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLSD

    DatePrice TargetRatingAnalyst
    7/18/2025$2.00Buy → Hold
    Stifel
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    7/18/2025Buy → Neutral
    H.C. Wainwright
    8/21/2024$6.00Buy
    Chardan Capital Markets
    6/25/2024$5.00Outperform
    Oppenheimer
    3/11/2022$11.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$19.00 → $9.00Outperform
    Wedbush
    7/29/2021$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLSD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    2/24/25 5:52:59 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    11/4/24 4:15:04 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    6/24/24 4:38:02 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    2/24/25 5:52:59 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Deignan Charles A.

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    1/10/25 4:30:10 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Chong Ngai Hang Victor

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    1/10/25 4:30:07 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Leadership Updates

    Live Leadership Updates

    View All

    Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

    ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. George Lasezkay, PharmD, JD, President and Chief Executive Officer, Clearside Biomedical, commented, "Tony is a highly respected member of our Board, bringing a wealth of strategic leadership experie

    11/4/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

    ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t

    7/11/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

    ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, Chair of the Clearside Board of Directors. "We believe Tony's significant experience driving value for biotech companies through successful pipeline development, financing, partnerin

    4/16/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    11/1/23 4:04:12 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    2/14/23 10:29:32 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    2/13/23 12:19:46 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    SEC Filings

    View All

    Clearside Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8-K - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/14/25 4:05:30 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Clearside Biomedical Inc.

    10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/8/25 4:05:49 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Clearside Biomedical Inc.

    DEF 14A - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/4/25 8:00:10 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

    - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME). XIPERE is approved for use in the United States, Canada, Australia

    7/23/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

    - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, Ga., July 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced plans to explore a full range of strategic alternat

    7/17/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

    ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the de

    5/21/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clearside Biomedical downgraded by Stifel with a new price target

    Stifel downgraded Clearside Biomedical from Buy to Hold and set a new price target of $2.00

    7/18/25 8:10:27 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Clearside Biomedical from Buy to Neutral

    7/18/25 8:08:24 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Clearside Biomedical from Buy to Neutral

    7/18/25 8:08:24 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Financials

    Live finance-specific insights

    View All

    Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

    ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid

    5/8/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    - Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside's SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the

    3/27/25 4:05:00 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

    ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call ca

    3/12/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care